Everything below concerns photodegradation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-05. Numbers and descriptions here follow the published literature rather than marketing material.
Peptides are short chains of amino acids whose physical and chemical stability depends on sequence, length, conformation, and the surrounding matrix. In the solid state, lyophilized powders are generally more stable than solutions because low water activity slows hydrolysis and oxidation. Residual moisture, oxygen, trace metals, and light can still promote degradation over time. Storage recommendations therefore balance temperature, humidity, and container integrity rather than relying on a single condition. The optimal condition for a given peptide is often determined empirically because no universal rule covers every sequence.
In aqueous solution, peptides are vulnerable to hydrolysis, oxidation, deamidation, and aggregation, with rates influenced by pH, temperature, buffer composition, and ionic strength. Acidic or neutral pH ranges often slow deamidation, while extreme pH can accelerate peptide bond cleavage. Dissolved oxygen and redox-active metal ions contribute to oxidation of methionine, cysteine, and tryptophan residues. Aggregation may be driven by hydrophobic interactions or by interfaces such as air-liquid and container surfaces. Because these pathways interact, solution storage usually requires tighter control than storage of dried material.
Aliquoting reduces repeated temperature cycling for solutions and reconstituted samples. If a peptide is supplied as a powder, reconstitution usually involves adding a suitable solvent gently along the vial wall. Mixing by inversion or slow swirling is preferred over vortexing, which can create air-liquid interfaces that promote aggregation or foaming. The resulting solution should be inspected for clarity, particles, and color before storage. Labels on aliquots typically include concentration, solvent, date, and lot number, and open questions remain about the best solvent for every sequence.
Quality control relies on analytical methods that detect changes in purity, identity, and concentration. Reverse-phase high-performance liquid chromatography separates the parent peptide from degradation products, while mass spectrometry confirms molecular mass. Water content can be measured by Karl Fischer titration, and amino acid analysis or peptide mapping may reveal sequence-level modifications. Stability studies compare stored samples against baseline material at defined intervals. Documentation should link each result to a lot number, storage condition, and test date so that trends can be reviewed.
Receipt and inventory practices begin with inspection of packaging, temperature indicators, and lot-specific documentation. A certificate of analysis typically reports purity, identity, and sometimes residual water or counterion content. Containers should be labeled with the peptide name, lot number, date received, and storage location. Before a sealed vial is opened, it is often equilibrated to room temperature to reduce condensation on the contents. Clean tools, gloves, and a designated workspace limit contamination and accidental adsorption losses.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid; may appear fluffy or crystalline |
| Solubility class | Water-soluble or sparingly soluble | Depends on sequence and counter-ion content |
| Typical storage temperature | -20 °C or lower for solids | Refrigeration may suffice for short-term use |
| Common analytical method | Reverse-phase HPLC | Purity and degradation products are often assessed by UV detection |
| Primary stability risks | Moisture, oxygen, light, heat | Aggregation and hydrolysis can also occur in solution |
After reconstitution, dividing the solution into single-use aliquots limits multiple warming and cooling events and reduces contamination risk. Low-binding polypropylene tubes are often preferred because peptides can adsorb to glass or untreated plastic surfaces. Filling headspace with nitrogen or argon can slow oxidation, and amber or foil-wrapped containers reduce photodegradation. Each aliquot should be labeled with peptide identity, concentration, date, and storage conditions. Frozen aliquots should be thawed quickly and kept on ice until use.
When a peptide arrives, the vial should be inspected for damage, and its label, lot number, and accompanying analytical data should be recorded. Cold vials should equilibrate to room temperature before opening to prevent condensation on the powder. Moisture uptake can reduce stability and complicate accurate weighing or reconstitution. Inventory systems that track date, quantity, and storage location help prevent unnecessary temperature cycling. Personnel should follow institutional or manufacturer instructions for any specific peptide.
Reconstitution is often performed with sterile water, buffer, or a water-miscible organic solvent, depending on solubility. The solvent should be added gently along the vial wall, and the solution mixed by gentle swirling rather than vigorous vortexing, which can cause foaming and surface denaturation. Some sequences require a small amount of base or acid to dissolve, followed by pH adjustment. Preparing a concentrated stock solution can simplify later dilution, but the stock itself may have limited stability. Records of solvent, concentration, and date support reproducibility.
Cold-chain shipping uses insulated containers, phase-change packs, and temperature indicators. Dry ice maintains -70 °C or lower but requires venting to avoid pressure buildup. Gel packs provide 2-8 °C for shorter transit. Upon arrival, recipients should record temperature indicators and transfer vials promptly to storage. Deviations from specified conditions should be documented and may require analytical re-check. The effect of a brief temperature excursion is peptide-specific and not always predictable from general rules.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
Temperature selection balances degradation rate against physical changes. Many lyophilized peptides are stored at -20 °C, while some modified or longer sequences require -80 °C for extended periods. Aqueous stock solutions are less stable and are often kept at -20 °C or below in single-use aliquots. Repeated freeze-thaw cycles can cause aggregation, precipitation, or loss of activity, so aliquoting before freezing reduces that risk. Frost-free freezers cycle above freezing and may be unsuitable for long-term peptide storage.
Container and environment choices matter. Peptides may adsorb to glass, plastic, or filter membranes, especially at low concentrations. Low-binding tubes and inert containers reduce loss. Moisture barriers include sealed bags with desiccant, and light protection uses amber vials or opaque wraps. Inert gas blankets can limit oxidation for sequences containing methionine, cysteine, or tryptophan. Buffers and pH also affect solution stability; extremes of pH accelerate hydrolysis and deamidation. These practices apply to research and manufacturing settings, not to any specific clinical use.
Peptides are short amino acid polymers whose stability depends on sequence, length, and chemical modifications. In dry form, most peptides are relatively stable because low water activity slows hydrolysis and other degradation. Residual moisture, oxygen, and light can still promote oxidation, deamidation, or aggregation over time. Storage recommendations therefore usually combine low temperature, desiccation, and protection from light. Because each peptide has distinct properties, no single condition fits every sequence.
Receiving a peptide begins with recording its identity, lot number, quantity, and arrival condition. Dry material is often kept in sealed containers with desiccant and an inert headspace to limit moisture and oxygen. Containers should be compatible with the peptide and solvent; some peptides adsorb to certain plastics or glass. Labels should include date, concentration, solvent, and storage location. A centralized inventory with temperature logs helps prevent loss and mix-ups.
Reconstitution involves adding a solvent to dry peptide, often water or a buffered solution. The chosen liquid should match the peptide's solubility and intended assay, and it should be free of contaminants. Gentle mixing or inversion reduces foaming and shear, which can damage some peptides. If the peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help. The final solution is typically clarified before use in analytical or laboratory procedures.
An exceptional case appears with the benzylideneprotecting group, which also admits reductive cleavage. This proceeds either through catalytic hydrogenation or with the hydride donor diisobutyl aluminum hydride (DIBAL). The cleavage with DIBAL deprotects one alcohol group, for the benzyl moiety stays as a benzyl ether on the second, sterically hindered hydroxy group.
Currently, the standard treatment is autografting which involves obtaining the donor bone from a non-significant and easily accessible site (i.e. iliac crest) in the patient own body and transplanting it into the defective site. Transplantation of autologous bone has the best clinical outcome because it integrates reliably with the host bone and can avoid complications with the immune system. But its use is limited by its short supply and donor site morbidity associated with the harvest procedure. Furthermore, autografted bones are avascular and hence are dependent on diffusion for nutrients, which affects their viability in the host. The grafts can also be resorbed before osteogenesis is complete due to high remodeling rates in the body. Another strategy for treating severe bone damage is allografting which transplants bones harvested from a human cadaver. However, allografts introduce the risk of disease and infection in the host. Bone tissue engineering presents a versatile response to treat bone injuries and deformations. Nanofibers produced via electrospinning mimics the architecture and characteristics of natural extracellular matrix particularly well. These scaffolds can be used to deliver bioactive agents that promote tissue regeneration. These bioactive materials should ideally be osteoinductive, osteoconductive, and osseointegratable. Bone substitute materials intended to replace autologous or allogeneic bone consist of bioactive ceramics, bioactive glasses, and biological and synthetic polymers.
Melanocytes and basal cells are embedded in the epidermal layer. Upon exposure to UVB rays, melanocytes will produce more melanin, a pigment that gives skin its color. UVB can cause the formation of freckles and dark spots, both of which are symptoms of photoaging; these are most common in people with fair or light skin. With frequent long-term exposure to UVB rays, signs of photoaging might appear, and precancerous lesions or skin cancer may develop as well as damage to DNA. UVA rays are able to penetrate deeper into the skin than UVB rays, damaging the dermal layer as well as the epidermal layer. The dermis is the second major layer of the skin, and it comprises collagen, elastin, and extrafibrillar matrix, which provides structural support to the skin. With chronic UVA exposure, damage to dermal collagen, elastin, and the extracellular matrix contributes to skin laxity, roughness, and wrinkling. Due to the presence of blood vessels in the dermis, UVA rays can lead to dilated or broken blood vessels, which are most commonly visible on the nose and cheeks. UVA can also damage DNA indirectly through the generation of reactive oxygen species (ROS), which include superoxide anion, peroxide, and singlet oxygen. These ROS damage cellular DNA as well as lipids and proteins.
=== Chemistry === Like the other noble gases, krypton is chemically highly unreactive. The rather restricted chemistry of krypton in the +2 oxidation state parallels that of the neighboring element bromine in the +1 oxidation state; due to the scandide contraction it is difficult to oxidize the 4p elements to their group oxidation states. Until the 1960s no noble gas compounds had been synthesized. Following the first successful synthesis of xenon compounds in 1962, synthesis of krypton difluoride (KrF2) was reported in 1963. In the same year, KrF4 was reported by Grosse, et al., but was subsequently shown to be a mistaken identification. Under extreme conditions, krypton reacts with fluorine to form KrF2 according to the following equation:
Sources: en.wikipedia.org
Missense mutations can render the resulting protein nonfunctional, due to misfolding of the protein. These mutations are responsible for human diseases, such as Epidermolysis bullosa, sickle-cell disease, SOD1 mediated ALS, and a substantial number of cancers. Not all missense mutations lead to appreciable protein changes. An amino acid may be replaced by a different amino acid of very similar chemical properties in which case the protein may still function normally; this is termed a conservative mutation. Alternatively, the amino acid substitution could occur in a region of the protein which does not significantly affect the protein secondary structure or function. Lastly, when more than one codon codes for the same amino acid (termed "degenerate coding"), the resulting mutation does not produce any change in translation and hence no change in protein is observed; degenerate coding would be classified as a synonymous substitution, or a silent mutation, and not a missense mutation.
As carbon dioxide concentrations rise, the rate at which sugars are made by the light-independent reactions increases until limited by other factors. RuBisCO, the enzyme that captures carbon dioxide in the light-independent reactions, has a binding affinity for both carbon dioxide and oxygen. When the concentration of carbon dioxide is high, RuBisCO will fix carbon dioxide. However, if the carbon dioxide concentration is low, RuBisCO will bind oxygen instead of carbon dioxide. This process, called photorespiration, uses energy, but does not produce sugars. RuBisCO oxygenase activity is disadvantageous to plants for several reasons:
=== The position of turtles === The placement of turtles has historically been highly variable. Classically, turtles were considered to be related to the primitive anapsid reptiles. In their comparative analysis of the timing of organogenesis, Werneburg and Sánchez-Villagra (2009) found support for the hypothesis that turtles belong to a separate clade within Sauropsida, outside the saurian clade altogether. Molecular work has usually placed turtles within the diapsids. As of 2013, three turtle genomes have been sequenced. The results place turtles as a sister clade to the archosaurs, the group that includes crocodilians, non-avian dinosaurs, and birds. A 2026 study found that they were nested within Archosauromorpha, with strong morphological support.
The Banting Postdoctoral Fellowship Program is administered by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, and the Social Sciences and Humanities Research Council of Canada. The fellowship provided up to two years of funding at $70,000 per year to researchers in health, natural sciences, engineering, social sciences and humanities.
==== Neurotransmitter receptors ==== DHEA has been found to directly act on several neurotransmitter receptors, including acting as a positive allosteric modulator of the NMDA receptor, as a negative allosteric modulator of the GABAA receptor, and as an agonist of the σ1 receptor.
Sources: en.wikipedia.org
== Antiviral drug resistance == Antiviral resistance can be defined by a decreased susceptibility to a drug caused by changes in viral genotypes. In cases of antiviral resistance, drugs have either diminished or no effectiveness against their target virus. The issue inevitably remains a major obstacle to antiviral therapy as it has developed to almost all specific and effective antimicrobials, including antiviral agents. The Centers for Disease Control and Prevention (CDC) inclusively recommends anyone six months and older to get a yearly vaccination to protect them from influenza A viruses (H1N1) and (H3N2) and up to two influenza B viruses (depending on the vaccination). Comprehensive protection starts by ensuring vaccinations are current and complete. However, vaccines are preventative and are not generally used once a patient has been infected with a virus. Additionally, the availability of these vaccines can be limited based on financial or locational reasons which can prevent the effectiveness of herd immunity, making effective antivirals a necessity. The three FDA-approved neuraminidase antiviral flu drugs available in the United States, recommended by the CDC, include: oseltamivir (Tamiflu), zanamivir (Relenza), and peramivir (Rapivab). Influenza antiviral resistance often results from changes occurring in neuraminidase and hemagglutinin proteins on the viral surface. Currently, neuraminidase inhibitors (NAIs) are the most frequently prescribed antivirals because they are effective against both influenza A and B.
== Enrichment steps == The peptide-mRNA:cDNA fusions can be selected over immobilized selection targets for several rounds (Figure 3). There might be a relatively high background for the first few rounds of selection, and this can be minimized by increasing selection stringency, such as adjusting salt concentration, amount of detergent, and/or temperature during the target/fusion binding period. Following binding selection, those library members that stay bound to the immobilized target are PCR amplified. The PCR amplification step will enrich the population from the mRNA-display library that has higher affinity for the immobilized target. Error-prone PCR can also be done in between each round of selection to further increase the diversity of the mRNA-display library and reduce background in selection. A less time-consuming protocol for mRNA display was recently published.
=== Origins === Synapsida, a clade that contains mammals and their extinct relatives, originated during the Pennsylvanian subperiod (~323 million to ~300 million years ago), when they split from the reptile lineage. Crown group mammals evolved from earlier mammaliaforms during the Early Jurassic. The cladogram takes Mammalia to be the crown group.
== History == Viscofan was founded in 1975, which is also when it began producing and selling its products. In 1988, Viscofan acquired the food group IAN (Industrias Alimentarias de Navarra), aiming to improve its presence in the Spanish market. Viscofan continued its international expansion by acquiring the German company Naturin GmbH & Co. in 1990 and opening new commercial offices overseas. Additional acquisitions included Gamex in the Czech Republic (1995), Trificel in São Paulo, Brazil (1995), Koteksprodukt AD in Serbia (2005), and the assets of Sweden's AB Tripasin (2005). In 2006, Viscofan broadened its footprint in the Americas by acquiring the U.S. and Mexican assets of Teepak. In 2008, Viscofan expanded its cogeneration plant in Spain. That same year, the company launched Viscofan Bioengineering, a business unit that merges bioscience and engineering to develop collagen-based products intended for tissue repair. The Bioengineering unit is located in Weinheim (Germany), where Viscofan also maintains a production site for collagen casings and an additional cleanroom facility for manufacturing medical-grade collagen materials. In 2009, Viscofan established Viscofan Technology (Suzhou) Co. Ltd. in China. The following year, it opened a converting plant in the country. In 2012, the company created Viscofan Uruguay S.A., followed by the opening of a collagen extrusion plant in China in 2013 and another extrusion facility in Uruguay in 2014. In 2015, Viscofan sold the IAN Group to focus on its casings business.
=== Occurrence === All berkelium isotopes have a half-life far too short to be primordial. Therefore, any primordial berkelium − that is, berkelium present on the Earth during its formation − has decayed by now. On Earth, berkelium is mostly concentrated in certain areas, which were used for the atmospheric nuclear weapons tests between 1945 and 1980, as well as at the sites of nuclear incidents, such as the Chernobyl disaster, Three Mile Island accident and 1968 Thule Air Base B-52 crash. Analysis of the debris at the testing site of the first United States' first thermonuclear weapon, Ivy Mike, (1 November 1952, Enewetak Atoll), revealed high concentrations of various actinides, including berkelium. For reasons of military secrecy, this result was not published until 1956. Nuclear reactors produce mostly, among the berkelium isotopes, berkelium-249. During the storage and before the fuel disposal, most of it beta decays to californium-249. The latter has a half-life of 351 years, which is relatively long compared to the half-lives of other isotopes produced in the reactor, and is therefore undesirable in the disposal products. The transuranic elements up to fermium, including berkelium, should have been present in the natural nuclear fission reactor at Oklo, but any quantities produced then would have long since decayed away.
Sources: en.wikipedia.org
Lyophilized peptides have low water activity, which slows hydrolysis and many oxidative pathways. Low temperatures further reduce residual chemical reactivity and microbial growth risk. The exact temperature depends on peptide stability data and expected storage duration.
Common pathways include hydrolysis, oxidation, deamidation, and aggregation. Their rates depend on pH, moisture, oxygen, trace metals, light, and temperature. Container surfaces and air-liquid interfaces can also promote loss or structural change.
No. Freezing can concentrate salts and buffer species, cause pH shifts, and damage peptides during ice crystal formation. Repeated freeze-thaw cycles are particularly disruptive. Refrigeration or single-use aliquots may be preferable for some solutions.
Allow the sealed vial to equilibrate to room temperature so condensation does not form on the powder or solution. Wipe the exterior with a suitable disinfectant if the workspace requires it. Open the vial in a clean, draft-free area to reduce contamination.